Other Events ·
CAMP4 Therapeutics approves inducement plan for up to 500,000 shares and amends equity incentive plan
CAMPCamp4 Therapeutics Corp
At its June 10, 2026 annual meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan to include outstanding pre-funded warrants in the evergreen provision calculation. Additionally, the Board approved a 2026 Inducement Plan allowing for the grant of up to 500,000 shares of common stock via various stock-based awards to new or rehired employees. The meeting also resulted in the election of Class II directors Steven Holtzman, Murray Stewart, and Richard Young, and the ratification of Ernst & Young LLP as the independent auditor. CAMP4 Therapeutics Corporation is a biotechnology company focused on developing therapeutics.